Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Enrollment
- 6
- Locations
- 1
- Primary Endpoint
- Percentage of Myeloma-specific T Cells ex Vivo Expanded Using Flow Cytometry
- Status
- Terminated
- Last Updated
- 10 years ago
Overview
Brief Summary
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma.
PURPOSE: This research study is looking at T cells in blood and bone marrow samples from patients with multiple myeloma.
Detailed Description
OBJECTIVES: Primary * To evaluate the feasibility of expanding myeloma-specific T cells using autologous ex vivo expanded B cells loaded with myeloma antigens as antigen-presenting cells (B-APCs) in peripheral blood and bone marrow samples from patients with multiple myeloma. Secondary * To examine the feasibility of selecting and expanding myeloma-specific T cells ex vivo using interferon γ release and CD3/CD28 stimulation. OUTLINE: Peripheral blood and bone marrow samples are collected periodically for laboratory studies. Samples are analyzed to assess the feasibility of expanding autologous B cells ex vivo using CD40L and IL-4; the antigen-presenting phenotype of autologous B-cell antigen-presenting cells (B-APCs) using flow cytometry; and the antigen-presenting function of B-APCs using ELISPOT and chromium-release assay. Myeloma-specific interferon γ secreting T cells are isolated and selected using Miltenyi beads. The selected myeloma-specific T cells are expanded ex vivo using anti CD3/CD28 beads.
Investigators
Zaid Al-Kadhimi
Principal Investigator
Barbara Ann Karmanos Cancer Institute
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Percentage of Myeloma-specific T Cells ex Vivo Expanded Using Flow Cytometry
Time Frame: Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
Secondary Outcomes
- Cell Counts of Myeloma-specific T Cells ex Vivo Expanded Before and After CD3/CD28 Stimulation(Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.)